Vicore Pharma Holding (NASDAQ:VCRE) Sees Significant Growth in Short Interest

Vicore Pharma Holding (NASDAQ:VCRE) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 10,709 shares, an increase of 941.7% from the October 15th total of 1,028 shares. Based on an average daily volume of 22,655 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VCRE. Chardan Capital assumed coverage on shares of Vicore Pharma in a report on Wednesday, November 4th. They issued a “buy” rating and a $15.00 target price on the stock. Wall Street Zen raised Vicore Pharma to a “hold” rating in a research report on Saturday, October 24th. Weiss Ratings began coverage on Vicore Pharma in a research note on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. Finally, Jefferies Financial Group assumed coverage on Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vicore Pharma presently has a consensus rating of “Hold” and an average price target of $20.00.

Vicore Pharma Price Performance

NASDAQ:VCRE traded up $0.08 during mid-day trading on Tuesday, hitting $11.35. The company’s stock had a trading volume of 24,639 shares, compared to its average volume of 26,533. Vicore Pharma has a fifty-two week low of $7.88 and a fifty-two week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs. Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.